SETDB1 and melanoma: Treatment with non‐specific SETDB1 inhibitors, such as mithramycin A and its analog mithralog EC‐8042, resulted in strong anti‐melanoma effects, suppressing SETDB1 expression and enhancing the efficacy of mitogen‐activated protein kinase (MAPK) inhibitors.